Literature DB >> 27229934

Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.

Stefano Frara1, Filippo Maffezzoni1, Gherardo Mazziotti2, Andrea Giustina3.   

Abstract

Diabetes mellitus is a frequent complication of acromegaly, a disease characterized by chronic hypersecretion of growth hormone (GH) by a pituitary adenoma. Diabetes occurs commonly but not only as a consequence of an insulin-resistant state induced by GH excess. The development of diabetes in patients with acromegaly is clinically relevant, since such a complication is thought to increase the already elevated cardiovascular morbidity and mortality risk of the disease. Emerging data suggest that a specific cardiomyopathy can be identified in acromegaly patients with diabetes. Moreover, the presence of diabetes may also influence therapeutic decision making in acromegaly, since traditional and newly developed drugs used in this clinical setting may impact glucose metabolism regardless of control of GH hypersecretion.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  acromegaly; cardiovascular risk; diabetes; medical therapy; pegvisomant; somatostatin analogs

Mesh:

Substances:

Year:  2016        PMID: 27229934     DOI: 10.1016/j.tem.2016.04.014

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  27 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Impact of acromegaly treatment on cardiovascular complications.

Authors:  Adriana G Ioachimescu
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

Review 3.  Somatostatin receptor ligands in the treatment of acromegaly.

Authors:  Monica R Gadelha; Luiz Eduardo Wildemberg; Marcello D Bronstein; Federico Gatto; Diego Ferone
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

5.  Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Authors:  Yash Chhabra; Caroline N Nelson; Monika Plescher; Johanna L Barclay; Aaron G Smith; Sof Andrikopoulos; Salvatore Mangiafico; David J Waxman; Andrew J Brooks; Michael J Waters
Journal:  FASEB J       Date:  2019-02-19       Impact factor: 5.191

Review 6.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

Review 8.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

Review 9.  [Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Authors:  S Petersenn; M Christ-Crain; M Droste; R Finke; J Flitsch; I Kreitschmann-Andermahr; A Luger; J Schopohl; G Stalla
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

10.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.